Influenza virus vaccine trivalent - Protein Sciences Corporation

Drug Profile

Influenza virus vaccine trivalent - Protein Sciences Corporation

Alternative Names: ASP-7374; FluBlok; Seasonal influenza vaccine - Protein Sciences Corporation; Trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine (FluBlok); UMN-05; UMN-0502

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Protein Sciences Corporation
  • Developer Astellas Pharma; Ildong Pharmaceutical; Laboratorios Liomont; Protein Sciences Corporation; UMN Pharma
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 10 Jan 2017 UMN Pharma terminates its licence for Influenza virus vaccine trivalent in Japan
  • 14 Oct 2016 Launched for Influenza virus infections (Prevention, In adults) in Mexico (IM)
  • 22 Sep 2016 Influenza virus vaccine trivalent licensed to Avanzcare in Middle East and North Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top